Dimensional Assessment of Psychotic Symptoms and Disorders

Dimensional assessment of psychotic symptoms and disorders represents a transformative framework in psychiatry that moves beyond traditional categorical labels towards continuous, spectrum-based metrics of symptom severity. Rather than assigning individuals to rigid diagnostic boxes, dimensional models capture the nuances of positive symptoms (such as hallucinations and delusions), negative symptoms (including social withdrawal and diminished expression), cognitive impairment and affective dysregulation along continuous scales. Approaches such as factor analysis, bifactor modelling, item response theory and network analysis have elucidated latent symptom dimensions, leading to refined rating instruments and dynamic symptom profiles. Integration of these clinical dimensions with neurobiological measures—such as structural and functional neuroimaging—and genetic risk profiling has facilitated transdiagnostic frameworks that span schizophrenia, bipolar disorder and schizoaffective conditions. This shift supports stratified medicine by linking specific symptom signatures to underlying pathophysiological pathways, guiding more personalised interventions, improving prognostic precision and informing the development of novel therapeutic targets. The global applicability of dimensional assessment is underscored by its utility in diverse clinical settings and its capacity to harmonise research across disciplines.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Dimensional Assessment of Psychotic Symptoms and Disorders publication trend

The graph below shows the total number of articles in dimensional assessment of psychotic symptoms and disorders across all publications each year (not limited to Nature Index journals).

Technical terms

Dimensional assessment: A measurement strategy that quantifies symptoms along continuous scales rather than assigning categorical diagnoses.

Bifactor model: A statistical framework in which all items load on a general factor alongside one or more specific factors, revealing both shared and unique variance.

Transdiagnostic: Refers to constructs or processes that apply across multiple traditional diagnostic categories.

Grey matter volume (GMV): The total volume of neuronal cell bodies, dendrites and unmyelinated axons in a brain region, often measured by MRI.

Brain–behaviour mapping: Analytical methods linking variation in symptoms to neural substrates, enabling predictive models of clinical phenotypes.

References

1. Factor analysis of lifetime psychopathology and its brain morphometric and genetic correlates in a transdiagnostic sample. Translational Psychiatry (2024).
2. Transdiagnostic dimensions of psychopathology at first episode psychosis: findings from the multinational EU-GEI study. Psychological Medicine (2018).
3. Mapping brain-behavior space relationships along the psychosis spectrum. eLife (2021).
4. Realising stratified psychiatry using multidimensional signatures and trajectories. Journal of Translational Medicine (2017).